Drug intelligence / Profile preview

AZD6793

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD6793 is an orally administered small molecule inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), developed by AstraZeneca. It is currently in Phase I clinical trials for the treatment of inflammatory diseases and chronic obstructive pulmonary disease (COPD). The drug acts by inhibiting IRAK4, a key signaling kinase involved in innate immune responses and inflammation. By targeting IRAK4, AZD6793 aims to modulate inflammatory pathways implicated in diseases such as COPD[1][5][7].

Targets

IRAK4 (Interleukin-1 receptor associated kinase 4)

Beyond the preview

Go deeper on AZD6793.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD6793.

Explore the full profile